

1632

Substitute for form 1449A/PTO				<div>COMPLETE IF KNOWN</div> <div>10/289180</div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	
				Filing Date	August 11, 2006
				First Named Inventor	La Monica, et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	ITR0073YP
Sheet	1	of	4		

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number (if known)		
		EPC	0 346 710 B1	Miles, Inc.	11/11/1993
		PCT	WO 01/014416 A2	Merck & Co., Inc.	03/01/2001
		PCT	WO 01/24832 A2	Pecher	04/12/2001
		PCT	WO 01/30382 A1	Aventis Pasteus Limited	05/03/2001
		PCT	WO 02/022080 A3	Merck & Co., Inc.	03/21/2002
		PCT	WO 02/38769 A2	Muller	05/16/2002
		PCT	WO 03/059379 A2	Pharmexa	07/24/2002
		PCT	WO 2004/072287 A1	Istituto Di Ricerche Di Biologia Molecolare	08/26/2004
		PCT	WO 2004/092216 A1	Transgene S.A.	10/28/2004
		PCT	WO 2004/099247 A2	Istituto Di Ricerche Di Biologia Molecolare	11/18/2004

Examiner Signature	/Magdalene Sgagias/	Date Considered	05/30/2010
-----------------------	---------------------	--------------------	------------

COMPLETE IF KNOWN

Application Number

~~IF IF KNOWN~~
~~10/589180~~

Filing Date

August 18, 2006

First Named Inventor

La Monica, et al.

Group Art Unit

Examiner Name _____

Sheet

2

of

2

Attorney Docket Number

ITR0073YP

Examiner
Initials*Cite
No.

U.S. Patent Document

Number

Kind
Code
(if known)Name of Patentee or Applicant
of Cited Document

Date of Publication of
Cited Document
MM-DD-YYYY

Examiner
Initials*
TMS

Cite
No.

Foreign Patent Document

Office

Number

Kind
Code
(if known)Name of Patentee or Applicant
of Cited Document

Date of Publication of
Cited Document
MM-DD-YYYY

MS

PCT WO 2005/019455 A1

Instituto Di Ricerche Di Biologia Molecolare

03/03/2005

Examiner
Signature

/Magdalene Sgagias/

Date Considered

05/30/2010

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the inventor. **ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. (M.S.)**

Substitute for form 1449B/PTO				COMPLETE IF KNOWN	
INFORMATION DISCLOSURE				Application Number	
STATEMENT BY APPLICANT				Filing Date	
(use as many sheets as necessary)				First Named Inventor	
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	
Sheet	3	of	4	ITR0073YP	

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/M.S./		Beauchemin, et al., "Isolation and Characterization of Full-Length Functional cDNA Clones for Human Carcinoembryonic Antigen", Mol. and Cell. Biol., Vol. 7, No. 9, pp. 3221-3230, Sept. 1987.
		Benchimol, et al., "Carcinoembryonic Antigen, a Human Tumor Marker, Functions as an Intercellular Adhesion Molecule", Cell, Vol. 57, pp. 327-334, April 21, 1989.
		Berinstein, et al., "Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: a Review", J. of Clinical Oncology, Vol. 20, No. 8, pp. 2197-2207, April 15, 2002.
		Chen, et al., "Enhancement of DNA Vaccine Potency by Linkage of Antigen Gene to an HSP70 Gene", Cancer Research, Vol. 60, pp. 1035-1042, February 15, 2000.
		Cheng, et al., "Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Mycobacterium tuberculosis Heat Shock Protein 70 Gene to an Antigen Gene", J. of Immunol., Vol. 166, pp. 6218-6226, 2001.
		Chester, et al., "Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer", Cancer Chemother. Pharmacol., Vol. 46 (Suppl) S2-S12, 2000.
		Gold, et al., "Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques", J. Exp. Med., Vol. 121, pp. 439-462 (1965).
		Hammarstrom, et al., "Is There a Role for CEA in Innate Immunity in the Colon", Trends in Microbiology, Vol. 9, No. 3, pp. 119-125, 2001.
		Kantor, et al., "Immunogenicity and Safety of a Recombinant Vaccinia Virus Vaccine Expressing the Carcinoembryonic Antigen Gene in a Nonhuman Primate", Cancer Research, Vol. 52, pp. 6917-6925, 1992.
		King, et al., "DNA Vaccines With Single-Chain Fv Fused To Fragment C Of Tetanus Toxin Induce Protective Immunity Against Lymphoma and Myeloma", Nature Medicine, Vol. 4, No. 11, pp. 1281-1286, November 1998.
		Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data", J. Mol. Biol., Vol. 183, pp. 1-12, 1985.
		Liu, et al., "Recombinant Adeno-Associated Virus Expressing Human Papillomavirus Type 16 E7 Peptide DNA Fused with Heat Shock Protein DNA as a Potential Vaccine for Cervical Cancer", J. of Virol., Vol. 74, No. 6, pp. 2888-2894, March 2000.
		Lund, et al., "Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system", Cancer Gene Therapy, Vol. 10, pp. 365-376, 2003.
		Montgomery, et al., "Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors", DNA and Cell Biology, Vol. 12, No. 9, pp. 777-783, 1993.
		Padua, et al., "PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia", Nature Medicine, Vol. 9, No. 11, pp. 1413-1417, November 2003.

Examiner Signature	/Magdalene Sgagias/	Date Considered	05/30/2010
--------------------	---------------------	-----------------	------------

Substitute for form 1449B/PTO				<div>COMPLETE IF KNOWN</div>	
<div>INFORMATION DISCLOSURE</div> <div>STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				Application Number	10/589180
				Filing Date	August 11, 2006
				First Named Inventor	La Monica, et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	ITR0073YP
Sheet	4	of	4		

NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	/Magdalene Sgagias/	Date Considered	05/30/2010
--------------------	---------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **PRIOR ART REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. (M.S.)**

Computer generated form *IDS Form* (IDS Folder), Merck & Co., Inc., -7/12/2001